Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for AKI Prevention in IMV Patients
NCT03206658Phase 3Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute kidney injury (AKI) comparing Spironolactone Arm with Placebo Arm (2 arms). Primary endpoint: Urinary biomarkers of acute kidney injury at 10 days. Status: unknown.
02
Drugs
spironolactone
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03206658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206658.